NTR

NTR Therapeutics was a biotechnology company focused on developing a novel class of cancer treatments using Gene-Directed Enzyme Prodrug Therapy (GDEPT). The company's technology utilized nitroreductase (NTR) enzymes to convert non-toxic prodrugs into potent cytotoxic agents specifically within tumor cells. Founded as a spin-out from the University of Auckland and the University of Oxford, NTR Therapeutics aimed to improve the selectivity and efficacy of chemotherapy. The company's approach involved the delivery of NTR genes to tumors followed by the administration of prodrugs like PR-104. While the technology showed promise in early research, the company is no longer active as a standalone entity.